News
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal's near-term development priority; broader 12-LOX platform remains a longer-term opportunityPONTE VEDRA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal...
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today highlighted recent scientific findings...
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq:...
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2 Meeting Scheduled for March 2026 PONTE VEDRA, Fla., Feb. 24, 2026...
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor
Company to also participate in Fireside Chat at Lytham Partners 2026 Investor Healthcare Summit on Thursday, January 15, 2026SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing...
Cadrenal’s Pipeline Looks Less Like a Microcap and More Like an Emergency Response System
PONTE VEDRA, FL / ACCESS Newswire / December 30, 2025 / Some companies enter a market because they see opportunity. Others step in because the situation has become unsustainable, and someone has to fix it. Cadrenal Therapeutics (NASDAQ:CVKD) falls into the second...
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On
PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its forgotten corners. In anticoagulation, those corners turned into entire neighborhoods. For years, the field centered itself around convenience drugs built for broad populations and clean...
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026
PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced that members of its...
Cadrenal’s Quiet Expansion Play Is Starting to Get Loud
PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) entered the back half of the year with a calm, almost surgical approach to building out its foundation. While most microcaps lean on noise to stay visible, Cadrenal has let its...
Cadrenal’s Anticoagulation Platform Is Expanding in a $40 Billion Market
PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) believes it continues to be misread by the market. Yes, the Company is intentionally narrowly focused. However, the lane it occupies is among the most undertreated areas in...